Tsutomu Takeuchi1, Ryo Nakajima2, Shuichi Komatsu2, Kiyotaka Yamazaki2, Tomohiro Nakamura2, Naoki Agata2, Ataru Igarashi3, Toshiro Tango4, Yoshiya Tanaka5. 1. Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. tsutake@z5.keio.jp. 2. AbbVie GK, Tokyo, Japan. 3. Department of Drug Policy and Management, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan. 4. Center for Medical Statistics, Tokyo, Japan. 5. The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyusyu, Japan.
Abstract
INTRODUCTION: The Adalimumab Non-interventional Trial for Up-verified Effects and Utility (ANOUVEAU) was a large-scale, multicenter, prospective, observational, single-cohort study that evaluated the effects of adalimumab (ADA) on rheumatoid arthritis (RA)-related work productivity and activity impairment (RA-related WPAI) and disease activity in routine rheumatology care in Japan. METHODS: Patients with RA were categorized as paid workers (PWs, ≥35 h/week), part-time workers (PTWs, <35 h/week), or homemakers (HMs, unemployed) and were administered the WPAI for RA (WPAI/RA) questionnaire. All patients who received ADA were followed for 48 weeks to evaluate safety and effectiveness. RESULTS: Of the 1808 patients analyzed, 825, 243, and 740 patients were PWs, PTWs, and HMs, respectively. WPAI/RA domain scores significantly improved at weeks 12, 24, and 48 in all groups, with maximum improvement observed for PWs (p < 0.05). Additionally, remission rates (according to Disease Activity Score 28, erythrocyte sedimentation rate, Simplified Disease Activity Index, or Health Assessment Questionnaire-Disability Index scores) and EuroQol 5-Dimension 3-Level scores significantly increased from baseline to 48 weeks in all groups (p < 0.0001). Analysis of patient subgroups revealed better WPAI/RA outcomes for patients who were biologic-naïve, treated with concomitant methotrexate, or with RA duration of ≤2 years (p < 0.05). The rate of serious adverse events over 48 weeks of ADA treatment was 5.23%. CONCLUSIONS: Treatment with ADA provided sustained improvement in WPAI and had an acceptable safety profile in patients with RA. FUNDING: AbbVie GK and Eisai Co., Ltd. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT01346488.
INTRODUCTION: The Adalimumab Non-interventional Trial for Up-verified Effects and Utility (ANOUVEAU) was a large-scale, multicenter, prospective, observational, single-cohort study that evaluated the effects of adalimumab (ADA) on rheumatoid arthritis (RA)-related work productivity and activity impairment (RA-related WPAI) and disease activity in routine rheumatology care in Japan. METHODS:Patients with RA were categorized as paid workers (PWs, ≥35 h/week), part-time workers (PTWs, <35 h/week), or homemakers (HMs, unemployed) and were administered the WPAI for RA (WPAI/RA) questionnaire. All patients who received ADA were followed for 48 weeks to evaluate safety and effectiveness. RESULTS: Of the 1808 patients analyzed, 825, 243, and 740 patients were PWs, PTWs, and HMs, respectively. WPAI/RA domain scores significantly improved at weeks 12, 24, and 48 in all groups, with maximum improvement observed for PWs (p < 0.05). Additionally, remission rates (according to Disease Activity Score 28, erythrocyte sedimentation rate, Simplified Disease Activity Index, or Health Assessment Questionnaire-Disability Index scores) and EuroQol 5-Dimension 3-Level scores significantly increased from baseline to 48 weeks in all groups (p < 0.0001). Analysis of patient subgroups revealed better WPAI/RA outcomes for patients who were biologic-naïve, treated with concomitant methotrexate, or with RA duration of ≤2 years (p < 0.05). The rate of serious adverse events over 48 weeks of ADA treatment was 5.23%. CONCLUSIONS: Treatment with ADA provided sustained improvement in WPAI and had an acceptable safety profile in patients with RA. FUNDING: AbbVie GK and Eisai Co., Ltd. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT01346488.
Entities:
Keywords:
Patient safety; Post-marketing surveillance study; Rheumatoid arthritis; TNF inhibitor; Work productivity and activity impairment
Authors: Ronald F van Vollenhoven; Mary A Cifaldi; Saurabh Ray; Naijun Chen; Michael H Weisman Journal: Arthritis Care Res (Hoboken) Date: 2010-02 Impact factor: 4.794
Authors: H G Raterman; J L Hoving; M T Nurmohamed; M M J Herenius; J K Sluiter; W F Lems; P P Tak; B A C Dijkmans; J Twisk; M H W Frings-Dresen; Alexandre E Voskuyl Journal: Scand J Rheumatol Date: 2010-03 Impact factor: 3.641
Authors: Victoria Bejarano; Mark Quinn; Philip G Conaghan; Richard Reece; Anne-Maree Keenan; David Walker; Andrew Gough; Michael Green; Dennis McGonagle; Ade Adebajo; Stephen Jarrett; Sheelagh Doherty; Lesley Hordon; Richard Melsom; Kristina Unnebrink; Hartmut Kupper; Paul Emery Journal: Arthritis Rheum Date: 2008-10-15
Authors: Christian Dejaco; Thomas Mueller; Omid Zamani; Ulrike Kurtz; Stefan Egger; Johannes Resch-Passini; Anna Totzauer; Babak Yazdani-Biuki; Thomas Schwingenschloegl; Peter Peichl; Angelika Kraus; Gerhard W Naerr Journal: Front Med (Lausanne) Date: 2022-06-02
Authors: Mary Lucy Marques; Alessia Alunno; Sofia Ramiro; Polina Putrik; Annelies Boonen; Marieke M Ter Wee; Louise Falzon Journal: RMD Open Date: 2021-02